Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Tabata, Chiharu ^a   Shibata, Eisuke ^a   Tabata, Rie ^b   Kanemura, Shingo ^a   Mikami, Koji ^a   Nogi, Yoshitaka ^a   Masachika, Eriko ^a   Nishizaki, Tomoyuki ^a   Nakano, Takashi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Hyogo Prefectural Tsukaguchi Hospital   (Japan)

Author keywords

HMGB1; Mesothelioma; Tumor marker

Indexed keywords

ASBESTOS; HIGH MOBILITY GROUP B1 PROTEIN; TUMOR MARKER;

AGED; ARTICLE; ASBESTOSIS; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PLEURA PLAQUE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN SYNTHESIS; UPREGULATION;

ADENOCARCINOMA; AGED; AREA UNDER CURVE; ASBESTOSIS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL LINE, TUMOR; FEMALE; HMGB1 PROTEIN; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84876667356     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-205     Document Type: Article

References (30)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005, 366:397-408. 10.1016/S0140-6736(05)67025-0, 16054941.
2. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005, 353:1591-1603. 10.1056/NEJMra050152, 16221782.
3. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960, 17:260-271. 1038078, 13782506.
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644. 10.1200/JCO.2003.11.136, 12860938.
5. Nowak AK, Lake RA, Kindler HL, Robinson BW. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002, 29:82-96. 10.1053/sonc.2002.30234, 11836673.
6. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362:1612-1616. 10.1016/S0140-6736(03)14794-0, 14630441.
7. Hollevoet K, Reitsma JB, Creaney J. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012, 30:1541-1549. 10.1200/JCO.2011.39.6671, 3383122, 22412141.
8. Bianchi ME, Beltrame M, Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science 1989, 243(4894 Pt 1):1056-1059.
9. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418(6894):191-195. 10.1038/nature00858, 12110890.
10. He M, Kubo H, Ishizawa K, Hegab AE, Yamamoto Y, Yamamoto H, Yamaya M. The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2007, 293:L1427-L1436. 10.1152/ajplung.00075.2007, 17951314.
11. Hamada N, Maeyama T, Kawaguchi T, Yoshimi M, Fukumoto J, Yamada M, Yamada S, Kuwano K, Nakanishi Y. The role of high mobility group box1 in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008, 39:440-447. 10.1165/rcmb.2007-0330OC, 18441281.
12. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995, 108:1122-1128.
13. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-3342. 10.1038/nri1594, 15803152.
14. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001, 108:949-955. 200958, 11581294.
15. Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, Rosas-Ballina M, Czura CJ, Huston JM, Miller E, Lin X, Sherry B, Kumar A, Larosa G, Newman W, Tracey KJ, Yang H. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006, 203:1637-1642. 10.1084/jem.20052203, 2118346, 16818669.
16. Takahashi K, Fukushima S, Yamahara K, Yashiro K, Shintani Y, Coppen SR, Salem HK, Brouilette SW, Yacoub MH, Suzuki K. Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart. Circulation 2008, 118(14 Suppl):S106-S1014.
17. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, Nakajima T, Komiya S, Maruyama I. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003, 48:971-981. 10.1002/art.10859, 12687539.
18. Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, McQuaid DB, Noerager BD, Gaggar A, Clancy JP, O'Neal W, Sorscher EJ, Abraham E, Blalock JE. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 2008, 178:822-831. 10.1164/rccm.200712-1894OC, 2566793, 18658107.
19. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007, 13:2836-2848. 10.1158/1078-0432.CCR-06-1953, 17504981.
20. Tang D, Kang R, Zeh HJ, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010, 1799:131-140. 10.1016/j.bbagrm.2009.11.014, 2818552, 20123075.
21. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360. 10.1038/35012626, 10830965.
22. Poser I, Golob M, Buettner R, Bosserhoff AK. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 2003, 23:2991-2998. 10.1128/MCB.23.8.2991-2998.2003, 152547, 12665595.
23. Völp K, Brezniceanu ML, Bösser S, Brabletz T, Kirchner T, Göttel D, Joos S, Zörnig M. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006, 55:234-242. 10.1136/gut.2004.062729, 1856519, 16118352.
24. Brezniceanu ML, Völp K, Bösser S, Solbach C, Lichter P, Joos S, Zörnig M. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 2003, 17:1295-1297.
25. Liu PL, Tsai JR, Hwang JJ, Chou SH, Cheng YJ, Lin FY, Chen YL, Hung CY, Chen WC, Chen YH, Chong IW. High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. Am J Respir Cell Mol Biol 2010, 43:530-538. 10.1165/rcmb.2009-0269OC, 19933377.
26. Rake C, Gilham C, Hatch J, Darnton A, Hodgson J, Peto J. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer 2009, 100:1175-1183. 10.1038/sj.bjc.6604879, 2669989, 19259084.
27. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980, 15:2736-2740.
28. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, Bubici C, Mossman BT, Pass HI, Testa JR, Franzoso G, Carbone M. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 2006, 103:10397-10402. 10.1073/pnas.0604008103, 1502469, 16798876.
29. Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, Gazdar AF, Pass HI, Yang H. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 2012, 227:44-58. 10.1002/jcp.22724, 3143206, 21412769.
30. Carbone M, Yang H. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res 2012, 18:598-604. 10.1158/1078-0432.CCR-11-2259, 3291331, 22065079.